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Vasovagal Syncope in the Older Patient
Maw Pin Tan, BMEDSCI, BMBS, MRCP,* Steve W. Parry, MBBS, PHD, FRCP*†
Newcastle upon Tyne, United Kingdom
Vasovagal syncope (VVS) has been diagnosed with increasing frequency in older patients since the head-up tilt-
table test (HUT) was described over 2 decades ago. The incidence and prevalence of VVS in this age group re-
mains unknown. Older individuals are more likely to display a dysautonomic hemodynamic pattern with a pre-
dominantly hypotensive response during HUT. The positivity rates to passive and isoprotenerol-provoked HUT are
reduced with age, but positivity rates for glyceryl-trinitrate-induced HUT are comparable with younger subjects.
Few studies into treatment strategies have included older subjects. This is a review of the existing literature on
the epidemiology, clinical characteristics, diagnostic tools, and treatment strategies for VVS in older patients,
highlighting important areas for future research. (J Am Coll Cardiol 2008;51:599–606) © 2008 by the
American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.11.025n
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syncope is defined as a transient, self-limiting loss of
onsciousness, with loss of postural tone, collapse, and
pontaneous recovery. The term “vaso-vagal” was first used
y Sir William Gowers in 1907 to describe a constellation of
vagal” symptoms, including epigastric, respiratory, and
ardiac discomfort occurring in association with vasomotor
pasm (1). Sir Thomas Lewis redefined vasovagal syncope
VVS) along pathophysiological lines of a fall in blood
ressure as an added phenomenon to a slowing in ventric-
lar rate in 1932 (2,3). Vasovagal syncope is now accepted as
he most common cause of syncope, accounting for up to
6% of syncopal episodes presenting to the emergency room
4,5). Vasovagal syncope in older people, however, remains
ontroversial and poorly understood.
pidemiology
he overall incidence of syncope in community-dwelling
lders was reported as 6.2 per 1,000 person-years (6), with
sharp rise in incidence to 16.9 and 19.5 per 1,000
erson-years for men and women older than age 80 years,
espectively. Vasovagal syncope was diagnosed in 21.2% of
ll cases, and the cause remained unknown for 36.6%, but
o age differential was available.
Vasovagal syncope in the elderly was assumed to be rare
7,8) until head-up tilt-table testing (HUT) was described
y Kenny et al. (9) as a diagnostic tool for VVS. Positive
UTs have since been found with increasing frequency in
he elderly with concomitantly higher rates of VVS diag-
rom the *Institute for Ageing and Health, Newcastle University, Newcastle upon
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ccepted November 12, 2007.osed (10). In a retrospective study of 1,180 patients
eferred for evaluation of syncope in a specialist unit, VVS
as diagnosed in 49% and 31% of subjects younger and
lder than 65 years, respectively (11,12). Any reported
ncidence or prevalence of VVS is likely to be an underes-
imate, as large numbers of cases of syncope remain unex-
lained owing to the lack of systematic evaluation of
yncope in common clinical practice (5). A recent study into
ystematic evaluation of syncope of patients admitted to the
mergency room diagnosed VVS in 190 (41%) of 465
atients (4), and the age distribution demonstrated 2 peaks
t the ages of 20 to 29 years and older than 70 years (13).
The natural history of VVS in older people is also
ncertain. In the younger population, syncopal symptoms
end to run a benign course and wane with maturity (14).
here also appears to be no increase in mortality in subjects
ith neurally mediated syncope (6). However, there have
een several case reports associating VVS with advanced
alignancy and other terminal conditions (15–18). Kapoor
t al. (8) observed that the mortality for patients age 60 years
nd older with noncardiovascular syncope or syncope of
nknown cause was 5 times higher than for patients younger
han the age of 60 years, while the mortality in the
ardiovascular subgroup was similar for both age groups.
he older age group was, however, more likely to have other
omorbid illnesses. Multivariate analysis revealed that in-
reasing age, congestive heart failure, and cardiovascular
ause of syncope were risk factors for overall mortality and
udden death (8).
The actual incidence and prevalence of VVS in the elderly
as not yet been established, but VVS is now being
iagnosed with increasing frequency in this age group,
uggesting a bimodal age distribution for this condition
12). Vasovagal syncope in the older population may not
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course commonly observed in
younger subjects (13).
Pathophysiology
The mechanisms underlying
VVS remain poorly understood.
The current wisdom suggests
that orthostasis results in venous
pooling and a reduction in ve-
nous return (19), although de-
bate continues on this issue
(20,21). It is believed that the
igorous contraction of the myocardium against an inade-
uately filled chamber then precipitates the Bezold-Jarisch
eflex, which results in paradoxical hypotension and brady-
ardia (19). In younger patients, investigations using cardiac
maging, neurochemical assays, and electrophysiological
nalyses performed during HUT have found an increase in
ympathetic nerve activity, serum epinephrine, and renin
esulting in tachycardia and an initial rise in blood pressure
n response to upright tilt (22). Before the onset of syncope,
sudden withdrawal in sympathetic drive evidenced by a
eduction in sympathetic nerve activity (23), myocardial
ontractility (24), circulating norepinephrine, renin, and
ndothelin is observed (22). Increased cardiac vagal tone
25) and vasopressin levels (26) are observed after the onset
f syncope. The mean age of subjects in the above studies
as 42.5 years. Their generalizability to the older patient
ith VVS must, therefore, be open to question.
There are limited data on the pathophysiology of VVS
pecific to the elderly, though several age-related factors
ay predispose the older patient to VVS. Unlike younger
dults, an overlap often occurs with orthostatic hypotension
nd carotid sinus hypersensitivity (27,28). The elderly are
ore likely to have coexisting medical conditions, including
ypertension, and tend to be on more medications (8,29).
iese et al. (30) actually suggested that the elderly have
reater arterial pressure “reserve” for the maintenance of
onsciousness, as the systolic blood pressure was not signif-
cantly different at tilt-induced syncope despite a signifi-
antly higher baseline systolic pressure, and older subjects
lso demonstrated longer time to tilt positivity (30).
Humoral responses to orthostasis do appear to differ with
ncreasing age. Plasma renin activity declines with age,
uggesting that blood pressure during orthostasis is main-
ained by sympathetic mechanisms rather than the renin-
ngiotensin system in the elderly (31). Vasovagal patients
ge65 years possess higher baseline epinephrine levels but
educed epinephrine surge, but similar norepinephrine levels
n response to tilt-table testing in comparison with patients
ge 35 years (32). Plasma catecholamines, however, do
ot accurately measure changes in sympathetic activity, as
heir levels are dependent on rate of release, clearance, and
Abbreviations
and Acronyms
ACE  angiotensin-
converting enzyme
ATP  adenosine
triphosphate
GTN  glyceryl trinitrate
HF-HRV  high-frequency-
heart rate variability
HUT  head-up tilt-table
test(ing)
VVS  vasovagal syncopeime delay of circulation. aRuiz et al. (33) found that age was the single determinant
f significantly lower low-frequency and high-frequency
HF)-heart rate variability (HRV) during supine rest and
pright tilt (33). Low-frequency heart rate variability is an
ndex of sympathetic activity whereas HF-HRV reflects
arasympathetic activity. This study, therefore, suggests an
verall blunting of autonomic response with age, supporting
imilar findings from earlier studies (34,35).
Brignole et al. (36) described 3 different patterns of
esponses to HUT. Younger subjects tended to exhibit the
lassical vasovagal response during which blood pressure and
eart rate parameters remained constant before a cata-
trophic reduction in heart rate and/or blood pressure
eralded the onset of symptoms. Older subjects tended to
emonstrate a dysautonomic response, a more gradual drop
n blood pressure from the initiation of upright tilt or
dministration of glyceryl trinitrate (GTN), which was
ssociated with carotid sinus hypersensitivity (36). This
nding was not observed by Kochiadakis et al. (37), who
ound similar responses in both age groups. Both studies as
ell as that of Kurbaan et al. (38) found that younger
ubjects were more likely to have a bradycardic response,
hereas older participants were more likely to have a
ypotensive response (36–38).
The current knowledge about the pathophysiology of
VS is generated mainly from adolescents and young adults
nd cannot, therefore, be directly extrapolated to older
eople with the same condition. A simplistic view of the
imodal distribution of VVS prevalence would be that
ntianginals and antihypertensive agents cause the older-age
eak, but it is more likely that VVS in the elderly is a more
omplex disorder, associated with other age-related changes
n physiology, comorbid conditions, and drug therapy than
ts younger counterpart.
linical Features
he classical prodrome of pallor, sweatiness, nausea, ab-
ominal discomfort, dizziness, or lightheadedness often
ccompanies VVS. In the elderly, however, this prodrome is
ore likely to be short or even nonexistent (28,39,40). The
istory of syncopal episodes in terms of length of time
etween symptom onset and presentation is also likely to be
horter (36). While injuries are common in older patients
ith carotid sinus hypersensitivity, another neurally medi-
ted cause of syncope that often overlaps with VVS (41),
here are no data on the risk of injury in older patients with
VS.
Vasovagal syncope can be precipitated by prolonged
tanding or sitting, hot environments, dehydration, systemic
llness, emotional stress, fear, pain, venepuncture, and alco-
ol. Older people are more likely to be on prescription and
ver-the-counter medications. Chronic treatment with
ngiotensin-converting enzyme (ACE) inhibitors, long-
cting nitrates, and calcium-channel blockers with or without
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February 12, 2008:599–606 VVS in the Older Patientoncurrent diuretic therapy is associated with an increased
usceptibility to a hypotensive response to HUT (42).
Carotid sinus hypersensitivity, a related neurally mediated
isorder, has been associated with unexplained falls in the
lderly (43). The elderly often experience amnesia for loss of
onsciousness in relation to carotid sinus hypersensitivity,
ationalizing their falls to slips and trips (44). There has
een 1 case report linking VVS to unexplained falls in an
lderly patient (40).
Seizure-like episodes can occur during VVS, and these
an be clinically indistinguishable from epileptic seizures.
wo important studies have elegantly demonstrated positive
esponses to HUT with reproduction of convulsive re-
ponses in patients with treatment-resistant epilepsy
45,46). The mean ages of subjects in these studies were 29
nd 38.9 years, respectively, and, hence, should be inter-
reted with caution with regard to older people.
In older individuals, periods of cerebral hypoperfusion
uring hypotension or bradycardia may threaten areas of
oor cerebral circulation resulting in watershed infarcts, or
pparent transient ischemic attacks (47). This relationship
as been poorly described in the literature but may be a
ommon occurrence in clinical practice (48,49). Ballard
t al. (50) found that 77% of patients with Lewy body
ementia and 57% of patients with Alzheimer’s disease had
eurocardiovascular instability, the collective term for or-
hostatic hypotension, VVS, carotid sinus hypersensitivity,
nd related disorders. The degree of hypotensive response in
ubjects with carotid sinus hypersensitivity correlated with
he severity of cerebral white matter hyperintensities on
agnetic resonance imaging, which are associated with
ognitive impairment (51).
Vasovagal syncope is associated with psychological dis-
ress and reduced quality of life (52–55). Older patients
ere not deliberately excluded from any of the studies in the
receding text, but the mean age of the subjects with VVS
ncluded, 334 patients in total, was 46 years. In the elderly,
alls result in significant loss of confidence, fear of falling
56), loss of independence, and increased likelihood of
ubsequent institutionalization (57). There are no compa-
able data supporting such adverse psychological and social
equelae in older syncopal patients.
The majority of the information on the clinical charac-
eristics of VVS in the elderly had to be extrapolated from
tudies involving mainly younger subjects with VVS or
iterature on related disorders in the elderly. There are
urrently no published studies looking directly at the pre-
enting features, natural history, physical consequences, and
sychological morbidity of VVS in the elderly.
nvestigations
istory can be misleading in the older patient with VVS
ue to a short or nonexistent prodrome (58) and the lack of
ollateral histories (27). Nonetheless, a detailed history
including an accurate medical history and drug history), ihysical examination, and surface electrocardiogram (ECG)
emain the cornerstones of the evaluation of the older
atient with suspected VVS.
Although it now seems that VVS is far more common
han previously thought in old age, cardiac syncope increases
harply in incidence with age and is known to be associated
ith increased mortality (6,8). It is, therefore, important to
rst rule out cardiac causes of syncope in an older person
resenting with a history of loss of consciousness. A
revious history of heart disease predicts cardiac syncope
ith 95% sensitivity and 48% specificity, and its absence
xcludes a cardiac cause in 97% (59). It is also important to
onsider life-threatening acute illnesses such as pulmonary
hromboembolism, gastrointestinal hemorrhage, and septi-
emia. Whereas neurological causes of loss of consciousness
hould be considered, investigations with brain computed
omography, carotid Doppler ultrasonography, and electro-
ncephalograms have low yields and are only likely to be
ositive in patients with focal seizures or focal deficits on
hysical examination (60).
The history, physical examination, and surface ECG can
e diagnostic in VVS (59). Where uncertainty remains,
UT is the diagnostic test of choice (9,61,62). It may also
e useful to demonstrate the prodrome and diagnosis to the
atients. During a HUT, the patient is tilted up to between
0° to 70° on a tilt-table with a footplate during continuous
CG and blood pressure monitoring, usually with no
harmacologic challenge initially (61,62). In the elderly, the
ensitivity of drug-free passive HUT is relatively low (32%
o 36%) (29,63) compared with 67% to 74% in all age
roups (9,64).
If no symptoms are observed after 20 to 30 min, 400 g
f sublingual GTN can be administered as a provocation
gent (the Italian protocol) (61,65), though passive tilt
rotocols of 30- to 45-min duration remain widely in use
62). Drug provocation with GTN produces a positivity rate
60% to 78%) comparable to younger age groups (66,67).
hortened nitrate-provoked HUT protocols with the ad-
inistration of 400 to 800 g of GTN immediately after
pright-tilt, and a limited test duration of 15 to 25 min,
ave also been described (68,69). These protocols have not
een formally evaluated in older patients but may be useful
n patients who are unable to tolerate prolonged upright
osture due to frailty or medical problems such as back pain
nd neurologic deficits.
Incremental infusion of isoprotenerol from 1 to 3 g/min
uring HUT increases the positive rate of tilt-testing by
8% to 33% in the elderly (10,63). Positive responses,
owever, diminish with age (10). Isoprotenerol is also
ontraindicated in patients with ischemic heart disease,
ypertension, left ventricular outflow tract obstruction, and
ortic stenosis and has to be used with caution in the
resence of dysrhythmias (62). Therefore, although nitrate-
rovoked tilt testing is well tolerated by the elderly (70),
soprotenerol-provoked tilt testing is frequently relatively or
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VVS in the Older Patient February 12, 2008:599–606bsolutely contraindicated in older subjects (71) and has
ore frequent adverse effects (28,69).
Alternative provocative agents studied include clomipra-
ine, edrophonium, and isosorbide dinitrate (72–75). All
he above agents have mainly been tested in younger
ubjects (mean age  40.9 years), apart from edrophonium,
hich was tested in 2 studies involving patients up to the
ge of 94 years (mean age  52 years), demonstrating
quivalent positivity rates for isoprotenerol and edropho-
ium administration (74,75).
The use of adenosine or its precursor, adenosine triphos-
hate (ATP), as a provocative agent for HUT is controver-
ial (76). Adenosine and ATP in doses of up to 20 mg have
een reported to contribute to the diagnosis of VVS, and its
ositivity rate increases with age (77). It remains uncertain
hether a positive adenosine test indicates unmasking of
VS with cardioinhibition, sinus node disease, or a high-
egree atrioventricular block (76,78). From 2 studies involv-
ng subjects with mean ages of 73.65 and 72.4 years (79,80),
TP may also be useful in determining the likely response
o pacing intervention, though the putative underlying
radyarrhythmia remains obscure.
Nonpharmacologic provocation using lower body nega-
ive pressure has been described in subjects with a mean age
f 39 years (81,82). Positivity rates were reported as 84% to
5% (81), but 23% of asymptomatic control subjects also
emonstrated a positive response (82). This method is used
ccasionally in our laboratory and others (62), but there are
o data on the utility of lower body negative pressure tilt in
he elderly.
In summary, the elderly are more likely to require HUT
esting to confirm the diagnosis of VVS due to the lack of
ypical features and shorter or nonexistent prodromes. The
eproducibility of HUT in the elderly has been reported as
8% (83), which is at least comparable to the 65% to 85%
eproducibility rate in younger subjects (84,85). Both un-
rovoked HUT and GTN-provoked HUT are safe in the
lderly (86). The positivity rate of GTN-HUT in the elderly
s comparable to that seen in younger subjects, but the
ositivity rates of passive HUT and isoprotenerol-HUT
ecrease with increasing age.
reatment
s in all patients with VVS, obtaining a diagnosis followed
y reassurance and conservative advice is often adequate in
lder individuals. Patients should be advised to ensure
dequate hydration and to avoid possible precipitants. They
hould also be instructed to be vigilant for the onset of
rodromal symptoms and to initiate counter maneuvers
mmediately. Traditionally, patients were asked to lie down
mmediately with their feet propped up. Isometric handgrip,
rm tensing, and leg crossing (87–89) have now been shown
n a large randomized, controlled trial to reduce the recur-
ence of syncope in patients with VVS (90) (Table 1). This
ulticenter study did not include any patients older than dge 70 years, and patients on the control arm were random-
zed to conventional treatment, not placebo. Older individ-
als may find it difficult to perform such maneuvers due to
oexisting musculoskeletal and neurologic problems, but
hey remain useful adjuncts to other treatments.
Withdrawal of culprit medications should be considered.
iscontinuation of chronic vasodilator therapy, which
ncluded ACE inhibitors, calcium-channel blockers,
ong-acting nitrates, and diuretics, resulted in a reduction
n positive tilt response (42). However, over one-half of
he subjects continued to have a positive response to
ither passive or GTN-induced HUT 2 weeks after discon-
inuation of vasodilator therapy compared with 85% of
ontrol subjects who continued to take their vasoactive
edications (42).
Trials of preventive measures and pharmacologic agents
ave so far been disappointing. Elasticated compression
osiery is often tried but has only been formally tested in 3
atients with limited efficacy (91) and is often poorly
olerated by older people. Salt supplementation has been
hown to be effective in small studies in younger adults (92)
ut cannot be recommended in the older age group due to
he high prevalence of hypertension in this population.
Beta-adrenergic blockade was a widely used treatment in
he past, but recent randomized controlled trials have shown
imited efficacy with a potential for increased harm (93–95).
he only multicenter, double-blind, randomized controlled
rial (POST [Prevention Of Syncope Trial]) was published
n 2006 (95). This trial involved 208 patients randomized to
etoprolol or placebo. Subjects were then further stratified
ccording to ages of 42 or 42 years, and the authors
eported a weak trend to benefit in patients from the older
ge group. Previous small studies have suggested that
esponders to beta-blockers are older than nonresponders
96,97). Further randomized-controlled studies targeting
lder age groups may, therefore, be justified.
Fludrocortisone is now a commonly used treatment,
espite there being no randomized controlled trial in adults.
he only randomized placebo-controlled trial in a small
umber of children suggested that patients on the fludro-
ortisone arm had a significantly worse outcome than
lacebo (98). It is also poorly tolerated by older people, with
discontinuation rate of 33% due to hypokalaemia, hyper-
ension, heart failure, edema, and depression (99). A ran-
omized controlled trial on the treatment of VVS with
udrocortisone in adults is now underway (100).
Midodrine is a potent alpha-adrenergic receptor agonist,
hich stimulates peripheral vasoconstriction. It has demon-
trated impressive results in several small randomized con-
rolled trials (101–103). The main side-effects of supine
ystolic hypertension, urinary frequency, urgency, piloerec-
ion, worsening of angina, and cerebrovascular disease are
requently more troublesome in the elderly (104). Up to
5% of older subjects discontinued this drug within a year
ue to intolerance (104).
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February 12, 2008:599–606 VVS in the Older PatientSeveral other drugs including serotonin selective reuptake
nhibitors (105,106), disopyramide (107,108), etilefrine
109), theophylline (110), and scopolamine (111) have
hown promising results in small studies conducted mainly
n younger age groups. The few randomized placebo-
ontrolled trials published subsequently have, however,
emonstrated limited efficacy (106,112,113), with the ex-
eption of paroxetine (105). The only treatment assessed in
he elderly specifically is enalapril (114), which was tested in
placebo-controlled trial involving 24 subjects with symp-
om resolution in all subjects in the enalapril arm compared
ith symptom resolution in only 2 subjects in the placebo
rm (114). At present, the treatments noted in the preced-
ng text cannot be recommended until they have been
urther evaluated in adequately powered randomized,
lacebo-controlled trials.
Tilt training or orthostatic training has been assessed in
everal small studies with encouraging results (115–119).
atients are exposed to orthostasis either as inpatients with
ncreasing periods of upright tilt or at home by standing
gainst a wall for varying periods of time. The 2 controlled
rials so far (120,121), which randomized subjects to ortho-
tatic training or conventional treatment, have demon-
trated limited efficacy for orthostatic training. The mean
ge of subjects recruited to all the above studies was only
reatment Options for VVS and Their Usefulness in the Younger an
Table 1 Treatment Options for VVS and Their Usefulness in the
Treatment Modalities Younger Popu
Physical counter maneuvers (87–90) Reduction in median yearly symptom bu
Withdrawal of chronic vasodilator
therapy (42)
No specific studies involving younger sub
Salt supplementation (92) Significant increase in plasma volumes,
and reduction in baroreflex sensitivity
study  41.2  4.1 yrs
Beta-adrenergic receptor blockade
(93–95)
Limited efficacy in RCT (95)
Fludrocortisone (100) No published RCT; significant increase in
involving children (98)
Midodrine Effective in small RCTs (101,102)
Serotonin selective reuptake inhibitors 1 RCT suggesting paroxetine efficacious
benefit with fluoxetine (106); mean ag
were 42 and 45 yrs
ACE inhibitors No published studies
Disopyramide Effective in uncontrolled studies (107,10
suggested no benefit over 1 week (11
Scopolamine No reduction in tilt-induced syncope in 1
mean age of participants in RCT was
Tilt training No benefit in small RCTs due to poor com
of participants in studies was 38.8 yrs
Permanent cardiac pacing
(124,126–128)
Controversial evidence base; placebo-con
CE  angiotensin-converting enzyme; RCT  randomized controlled trial; VVS  vasovagal synco8.8 years. Their findings may not, therefore, apply to older ieople who may find standing against the wall for 15 to 40
in up to twice a day too physically challenging.
Several multicenter, randomized, controlled trials have
nvestigated the use of a permanent pacemaker for the
reatment of patients with cardioinhibitory VVS (122–126).
he results are mixed with the 2 double-blind placebo-
ontrolled studies demonstrating no efficacy for perma-
ent pacemakers (124,126 –128). This lack of efficacy
ould be influenced by the pacing modes used or the
election criteria for potential subjects. Recent small
ingle-blind studies reported a significant reduction in
ymptom recurrence using a new contractility-driven
DDR pacing (129) and closed-loop stimulation com-
ared with conventional DDI pacing (125). Further
tudies using either contractility-driven or closed-loop
timulation modes of cardiac pacing with more specific
nclusion criteria are now required.
The treatment options for VVS remain limited, with
isappointing results from the handful of large multi-
enter placebo-controlled trials published. With the ex-
eption of the pacemaker studies in which the mean ages
f subjects ranged from 50 to 74 years (122–126), few of
he studies published so far have included the elderly, the
ean age of subjects in most studies not exceeding 45
ears with only 1 study specific to the elderly (114). With
er Populations
ger and Older Populations
Older Population
1 RCT No subject age 70 yrs included in RCT; ability to
perform counter maneuvers may be limited by
physical disabilities
Case-control study of 45 patients (mean age 71  8
yrs) showing a reduction in follow-up tilt positivity
to 52% in off-vasodilator group vs. 85% in on-
vasodilator group
ed orthostatic tolerance,
age of participants in
No evidence base in older subjects; risk of
cardiovascular complications with high salt intake
Age 42 yrs predictor of response in uncontrolled
study (97) and trend toward efficacy in RCT (95)
tom recurrence in 1 RCT Poorly tolerated; 33% drug discontinuation rate (99)
Older patients included in 1 small RCT (103);
25% discontinuation rate
1 RCT demonstrating no
participants in RCTs
No evidence base in older subjects
1 small placebo-controlled trial of 24 elderly subjects
showed significant benefit over 1 yr in patients
receiving enalapril
all RCT of 22 patients Maximal age of participants in uncontrolled studies
of 10 and 15 subjects were 74 and 78 yrs
f 60 participants (113);
2 yrs
No evidence base in older subjects
ce (120,121); mean age No evidence base in older subjects
studies show no benefit No specific studies for the elderly; mean ages of
participants in RCTs were 50 to 74 yrsd Old
Youn
lation
rden in
jects
increas
; mean
symp
(105);
es of
8); sm
2)
RCT o
32  1
plian
trolledncreasing evidence of a divergence in the pathophysiol-
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VVS in the Older Patient February 12, 2008:599–606gy underlying VVS in the elderly and younger subjects,
ore studies should be conducted specifically in older
ubjects in the future.
onclusions
asovagal syncope is emerging as an increasingly important
ause of syncope in older people. The disease pattern
ppears to differ from VVS in younger subjects, with a
ysautonomic response more likely during diagnostic HUT
nd a higher proportion of hypotensive response in com-
arison with that seen in younger subjects. Head-up tilt-
able testing is also more often required in the elderly due to
he lack of prodromal symptoms. Current available strate-
ies for treatment are limited. Further research on all aspects
f this common disorder, from epidemiology to treatment
trategies, is, therefore, imperative in this patient group.
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